Advair Relaunch And Nasal Naloxone Nod Raise Hikma’s Expectations
Also Strikes Branded Injectables Deal With Melinta For MENA Region
Fresh from resuming launch of its generic version of Advair in the US, Hikma has also been boosted by an FDA approval for its 505(b)(2) naloxone 8mg nasal spray. Both developments are expected to drive the firm’s generics business to the top end of its guidance for 2021, management revealed.
